Results 61 to 70 of about 2,782 (157)

Analysis and Characterization of Kisspeptin and Its Analogues in Serum and Urine Samples by Liquid Chromatography–High‐Resolution Mass Spectrometry for Doping Control Purposes

Drug Testing and Analysis, Volume 18, Issue 7, Page 862-876, July 2026.
Sensitive LC‐HRMS methods were established for the detection of kisspeptin and its analogues in serum and urine, alongside their analytical and metabolic characterization. Stability studies were conducted in serum, plasma, and urine, highlighting the importance of appropriate sample handling for reliable anti‐doping analysis.
Sophia Krombholz, Linus Korsmeier, Andreas Thomas, Mario Thevis   +3 more
wiley   +1 more source

Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.
Tirzepatide 15 mg and cagrilintide–semaglutide (CagriSema) achieve the greatest percent body weight reduction (−17.97% and −17.46%, respectively) and the highest rates of ≥ 20% weight loss versus placebo in this network meta‐analysis of 25 randomized trials.
Sultan Hamarsheh, Abdel Rahman Jaber, Omar Abu‐Khazneh, Celina R. Andonie, Saleem Majadleh, Anwar Zahran, Hazem Ayesh   +6 more
wiley   +1 more source

Additional file 2 of The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile

, 2021
Additional file 2.
Larsen, Anna Thorsø, Gydesen, Sofie, Sonne, Nina, Karsdal, Morten Asser, Henriksen, Kim   +4 more
openaire   +1 more source

Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article

Indian Journal of Endocrinology and Metabolism
Obesity is a heterogeneous, complex, and chronic disease that has a detrimental impact on disability-adjusted life years across the globe. Recent advancements in our understanding of gut-brain communication at the molecular level have driven the ...
Wael R. Sidrak, Sanjay Kalra, Atul Kalhan   +2 more
doaj   +1 more source

DATTs: A Database of Disease‐Associated Therapeutic Targets With Required Actions for Treatment

Molecular Informatics, Volume 45, Issue 7, July 2026.
DATTs is a new database of therapeutic protein targets. The available information includes disease–target protein associations and the actions of drugs on these proteins required for therapeutic effects (e.g., activation, inhibition, or target). DATTs currently includes information on 613 diseases, 1475 target proteins, and 7415 disease–protein ...
Ryusuke Sawada, Noriko Yuyama Otani, Michio Iwata, Tomokazu Shibata, Shujiro Okuda, Hiroyo Nishide, Ikuo Uchiyama, Yoshihiro Yamanishi   +7 more
wiley   +1 more source

SURPASS‐CVOT and the Emerging Biology of Cardiometabolic Benefit

Diabetes, Obesity and Metabolism, EarlyView.
Salvatore Corrao, Francesco Cosentino, Massimo Federici   +2 more
wiley   +1 more source

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5915-5925, July 2026.
ABSTRACT Aims Petrelintide is a long‐acting amylin analogue in development for weight management. The safety, tolerability, pharmacokinetics, and pharmacodynamics of petrelintide were evaluated in single ascending dose (SAD) and multiple ascending dose (MAD) trials. Materials and Methods Both trials were randomized, placebo‐controlled, and double‐blind.
Minna Brændholt Olsen, Jon Griffin, Ulrike Hövelmann, Stanislava Macura, Berith Fredsted Hagen, Dan Hesse, Tim Heise   +6 more
wiley   +1 more source

Additional file 1 of The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile

, 2021
Additional file 1.
Larsen, Anna Thorsø, Gydesen, Sofie, Sonne, Nina, Karsdal, Morten Asser, Henriksen, Kim   +4 more
openaire   +1 more source

Metabolic Syndrome and Pharmacological Interventions in Clinical Development

Diabetology
Metabolic syndrome prevalence is between 24 and 27% and poses a significant risk for the development of atherosclerotic cardiovascular disease (ASCVD), type 2 diabetes (T2D), or other comorbidities. Currently, no drugs are approved for metabolic syndrome
Eugen Javor, David Šarčević, Arnes Rešić   +2 more
doaj   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Cocaine Use Disorder: Clinical Observations and Underlying Mechanisms

Fundamental &Clinical Pharmacology, Volume 40, Issue 4, July 2026.
ABSTRACT Background Cocaine use disorder (CUD) remains a major public health concern, characterized by high relapse rates and the absence of approved pharmacological treatments. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), widely prescribed for metabolic disorders, modulate mesolimbic reward pathways and have been proposed as potential ...
Céline Eiden, Ghjulia Chautard, Anne Batisse, Aurélie Aquizerate, Amandine Luquiens, Hélène Donnadieu, Jean‐Luc Faillie, Hélène Peyriere   +7 more
wiley   +1 more source